• Neurocrine Biosciences (NasdaqGS:NBIX) has started a Phase 2 clinical trial of its investigational compound NBI-1065890 for tardive dyskinesia.
• The company is building on its existing VMAT2 inhibitor franchise and prior FDA approvals in this therapeutic area.
• The study is designed to explore whether NBI-1065890 could offer a differentiated, longer-acting treatment option for patients.

For you as an investor, this new trial sits squarely in Neurocrine’s core expertise in movement disorders, where it already has FDA approved VMAT2 inhibitor therapy. Expanding within an area it knows well keeps the focus on neurological and psychiatric conditions, which remain a key theme for the company and the sector. Tardive dyskinesia continues to be an area of clinical need, so any additional treatment options tend to attract close attention from the healthcare community.

Phase 2 is still an early stage. However, each step like this can influence how you view the depth and diversity of Neurocrine’s pipeline. The outcome of NBI-1065890’s development may affect how the company positions its tardive dyskinesia portfolio over time, including how it balances existing therapies with potential longer-acting options.

Stay updated on the most important news stories for Neurocrine Biosciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Neurocrine Biosciences.

Quick Assessment

• ✅ Price vs Analyst Target: At US$141.20 versus a consensus target of US$179.59, the shares sit about 27% below analyst expectations.
• ✅ Simply Wall St Valuation: Simply Wall St values the stock as trading 55.7% below its estimated fair value.
• ✅ Recent Momentum: The 30 day return of roughly 0.4% is positive, though fairly modest.

Check out Simply Wall St's in depth valuation analysis for Neurocrine Biosciences.

Key Considerations

• 📊 The new Phase 2 trial builds on Neurocrine’s existing VMAT2 inhibitor franchise and may strengthen its position in tardive dyskinesia if results are supportive.
• 📊 It may be useful to monitor trial milestones, updates around NBI-1065890’s dosing profile, and how management discusses integrating it with current tardive dyskinesia products.
• ⚠️ The key risk is clinical because Phase 2 outcomes for NBI-1065890 remain uncertain and may influence how investors view the value of this part of the pipeline.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Neurocrine Biosciences analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.